Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)

Next Previous
Trial Profile

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prasterone (Primary)
  • Indications Decreased libido
  • Focus Therapeutic Use
  • Acronyms Second Study
  • Sponsors Endoceutics

Most Recent Events

  • 29 Jul 2020 Planned End Date changed from 1 Mar 2021 to 6 Dec 2019.
  • 29 Jul 2020 Planned primary completion date changed from 1 Dec 2020 to 15 Aug 2019.
  • 15 Nov 2019 Planned initiation date changed from 1 Oct 2019 to 13 Nov 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top